Skip Navigation Links
11 January 2021

Oxford Cannabinoid Technologies Announces Changes to Executive Team

  • Dr John Lucas named Chief Executive Officer
  • Clarissa Sowemimo-Coker named Chief Operating Officer in addition to role as General Counsel

Oxford Cannabinoid Technologies (“OCT”), the UK-based pharmaceutical firm researching the potential of cannabinoids for treating a range of acute and chronic conditions, is today announcing changes to the company’s leadership team. The board of directors has named Dr John Lucas as Chief Executive, and Clarissa Sowemimo-Coker as Chief Operating Officer of OCT. The board believe that these changes will help to position OCT for future growth and development at an exciting time for the business.

OCT is specialising in the development of cannabinoid-based prescription drugs for the £44.5bn pain market. It has had an exclusive research partnership with Oxford University since 2017, and is initially targeting indications in serious pain conditions with two drug candidates, with pre-clinical studies currently underway.

Dr John Lucas joined OCT in August 2018 in the role of Chief Commercial Officer. He is well placed to take on the position as Chief Executive Officer, with a detailed knowledge of all aspects of the company’s business, and having been a key architect behind OCT’s strategy and development over the past three years. He has over twenty years of experience in the biotechnology industry, and before joining OCT held senior roles at Cizzle Biotechnology, Silence Therapeutics and Ilika plc. As a qualified US patent attorney, he also has expertise on commercial and IP matters across healthcare.

Clarissa Sowemimo-Coker is expanding her role to include serving as the Chief Operating Officer of OCT. She has been a key part of the leadership team since joining in December 2018 as General Counsel, a role she retains. As Chief Operating Officer, Ms Sowemimo-Coker will oversee operational issues, as well as being closely involved on the company’s strategic goals. She has responsibility for legal, compliance, D&I, people, culture and public relations. A qualified solicitor, she has previously held roles as senior in-house counsel in corporations including Hutchison 3G UK Ltd and Virgin Media Ltd.

Dr John Lucas, Chief Executive Officer of OCT said “OCT continues to make enormous strides, combining the medical potential of cannabinoids with the scientific rigour of pharmaceutical R&D to develop an exciting drug candidate pipeline. I am delighted to be leading the team as our drug development programme takes the next steps forward, enabling OCT to deliver real therapeutic solutions for patients.” 

Clarissa Sowemimo-Coker, Chief Operating Officer and General Counsel said “I look forward to helping John and the wider team build the business’s position as a global leader in the development of prescription medicines from cannabinoids  for patients with significant unmet medical needs. It has been an exciting journey over the past three years, and the coming phase looks set to be a period of further development and progress for the business.”

Neil Mahapatra, founder and Chairman of OCT said "Strengthening the leadership of our business is always a top priority, and this change in roles reflects the growing breadth and scope of OCT, helping to position the business for the future. Both John and Clarissa share a deep passion for our mission and a keen understanding of what must be done to achieve our ambitions. Their insight, and knowledge of the industry will be invaluable as we shape the path forward for OCT.”

Related News articles

  • Oxford Cannabinoid Technologies nearly ready for new Phase 1 trial

    14 November 2022 Proactive Interview
  • StockBox Premiere - Oxford Cannabinoid Technolgies - Programme 1

    06 October 2022 StockBox
  • StockBox Interview - Oxford Cannabinoid Technologies w/ Dr Valentino Parravicini, CSO

    05 October 2022 StockBox
  • StockBox Premiere with Oxford Cannabinoid, Poolbeg Pharma & Destiny Pharma

    05 October 2022 StockBox
  • Cannabinoid Medicine for Pain Treatment with Clarissa Sowemimo-Coker COO Oxford Cannabinoid

    22 August 2022 StockBox
  • Oxford Cannabinoid Technologies has good opportunities in both lead products says analyst

    26 July 2022
  • Outsourcing in Clinical Trials UK & Ireland 2022 Conference – Dr Valentino Parravicini’s Address

    20 June 2022 Conference
  • OCT Investor Update 30 May 2022 - Q&A Questions

    30 May 2022 Investor Questions
  • The Cannabis Conversation: Cannabis Vs. Opioids with Valentino Parravicini

    18 May 2022 Podcast
  • Investor Meet Company Q&A Session

    16 May 2022 Investor Meet
  • Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy

    25 April 2022 Scientific Advisory Board
  • Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial

    31 March 2022 Programme Update
  • Data from pre-clinical study show positive results

    08 March 2022 Research Update
  • Requisition of General Meeting - Update

    04 March 2022 General Meeting
  • Oxford Cannabinoid Technologies aims to get aggressive share of £42.5bln market by 2027

    24 February 2022
  • Requisition of General Meeting

    18 February 2022 General Meeting
  • Notice of Analyst and Investment Presentation - How to Register

    17 February 2022 Presentations
  • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

    18 November 2021 StemTech
  • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

    17 November 2021 R&D Support
  • Posting of Annual Report, Notice of AGM and Form of Proxy

    27 October 2021 Annual Report, Notice of AGM and Form of Proxy
  • OCT Results and Company Update

    18 October 2021 Results and Company Update
  • Final Results and Notice of Annual General Meeting 13th October 2021

    13 October 2021 RNS
  • Oxford Cannabinoid Technologies work on treatment for chronic, painful disease Trigeminal Neuralgia

    12 October 2021 Trigeminal Neuralgia Interview
  • Oxford Cannabinoid Technologies Targets Chronic Pain Condition with Latest Formulation

    11 October 2021 Program 2 Announcement
  • OCT Explore the Opioid Crisis and Chronic Pain Pandemic in Pharmafocus Magazine

    30 September 2021 Pharmafocus Article
  • Good shape, good budget and on track for Oxford Cannabinoid Technologies Holdings

    28 September 2021 Podcast
  • Oxford Cannabinoid Technologies' deal for exclusive access to Canopy Growth's cannabinoid library

    22 September 2021 Canopy Growth
  • Oxford Cannabinoid Technologies says admission to the OTCQB is a logical next step

    02 September 2021 US Market
  • Oxford Cannabinoid Technologies announces strategic partnership with Evotec

    06 July 2021 Partnership
  • Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

    Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

    24 June 2021 iCDP Speaker
  • Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

    Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

    22 June 2021 Meet the Team Interview Series
  • Oxford Cannabinoid Technologies Holdings plc to conduct live presentations to retail investors

    04 June 2021 Live Presentation
  • OCT Forges Partnership with Voisin Consulting Life Sciences

    OCT Forges Partnership with Voisin Consulting Life Sciences

    01 June 2021 OCT Partnership
  • Oxford Cannabinoid Technologies Announces Changes to Executive Team

    11 January 2021 Oxford Cannabinoid Technologies Announces Changes to Executive Team
  • OCT Company Values: How We Pursue Our Mission and Vision

    OCT Company Values: How We Pursue Our Mission and Vision

    01 December 2020 OCT Company Values
  • OCT - Meet the Team Interview Series: Valentino Parravicini, Chief Scientific Officer

    Meet the Team Interview Series: Dr Valentino Parravicini, Chief Scientific Officer

    26 October 2020 Meet the Team Interview Series
  • OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

    07 September 2020 OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain
  • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

    OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

    28 July 2020 OCT Press Release
  • Cannabinoids in medicine part 5: Treating COVID-19

    17 June 2020 Open Access Government
  • Why the Government should continue to invest in Life Sciences post COVID-19

    Why the government should continue to invest in Life Sciences post COVID-19

    01 June 2020 OCT blog - John Lucas, COO
  • OCT researchers publish new study examining genes involved in treating neuropathic pain

    19 April 2020 OCT Press Release
  • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

    03 April 2020 OCT Press Release
  • Cannabinoids in medicine part 4: Epilepsy

    30 March 2020 Open Access Government
  • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

    07 January 2020 Open Access Government
  • Cannabinoids in medicine Part 2: Pain

    11 October 2019 Open Access Government
  • Cannabinoids in medicine Part 1: Cancer

    22 August 2019 Open Access Government
  • An interview with Neil Mahapatra

    08 January 2019 The Times Magazine
  • High life: the start-up hoping to unlock the secrets of medical cannabis

    09 August 2018 Evening Standard
  • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

    28 June 2018 OCT Press Release
  • Embracing the medical potential of cannabinoids

    01 June 2017 The Medicine Maker
  • Smashing the stigma with science

    01 June 2017 The Medicine Maker
  • Oxford University launches £10m research project into medical marijuana

    16 March 2017 Evening Standard
  • Oxford University launches £10m marijuana research programme

    16 March 2017 BBC
  • Oxford University to launch multimillion-dollar medical marijuana research program

    16 March 2017 CNBC
  • Oxford University to launch study on medical benefits of marijuana

    16 March 2017 The Telegraph
  • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

    15 March 2017 OCT Press Release